Evidence map›Paper›PMID 38313254›Full record

ArticlebioRxiv : the preprint server for biology2024

TDP-43 loss induces extensive cryptic polyadenylation in ALS/FTD.

Sam Bryce-Smith, Anna-Leigh Brown, Puja R Mehta, Francesca Mattedi, Alla Mikheenko, Simone Barattucci, Matteo Zanovello, Dario Dattilo, Matthew Yome, Sarah E Hill and 14 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 5 institutions in 2 countries.

Sam Bryce-SmithUCL Queen Square Motor Neuron Disease Centre, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, UCL, London, UK.ORCID 0000-0003-2087-5050
Anna-Leigh BrownUCL Queen Square Motor Neuron Disease Centre, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, UCL, London, UK.ORCID 0000-0003-1493-208X
Puja R MehtaUCL Queen Square Motor Neuron Disease Centre, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, UCL, London, UK.ORCID 0000-0002-0255-407X
Francesca MattediUCL Queen Square Motor Neuron Disease Centre, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, UCL, London, UK.ORCID 0000-0002-0306-5796
Alla MikheenkoUCL Queen Square Motor Neuron Disease Centre, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, UCL, London, UK.ORCID 0000-0003-3400-9719
Simone BarattucciUCL Queen Square Motor Neuron Disease Centre, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, UCL, London, UK.
Matteo ZanovelloUCL Queen Square Motor Neuron Disease Centre, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, UCL, London, UK.ORCID 0000-0003-3343-1547
Dario DattiloUCL Queen Square Motor Neuron Disease Centre, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, UCL, London, UK.ORCID 0000-0003-2774-3835
Matthew YomeUCL Queen Square Motor Neuron Disease Centre, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, UCL, London, UK.
Sarah E HillNational Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, USA.ORCID 0000-0002-8499-7455
Yue A QiNational Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, USA.ORCID 0000-0003-1914-8710
Oscar G WilkinsUCL Queen Square Motor Neuron Disease Centre, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, UCL, London, UK.ORCID 0000-0002-3334-0568
Kai SunUCL Queen Square Motor Neuron Disease Centre, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, UCL, London, UK.
Eugeni RyadnovUCL Queen Square Motor Neuron Disease Centre, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, UCL, London, UK.ORCID 0009-0003-9921-1755
Yixuan WanUCL Queen Square Motor Neuron Disease Centre, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, UCL, London, UK.
NYGC ALS Consortium
Jose Norberto S VargasUCL Queen Square Motor Neuron Disease Centre, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, UCL, London, UK.ORCID 0000-0001-5529-0883
Nicol BirsaUCL Queen Square Motor Neuron Disease Centre, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, UCL, London, UK.ORCID 0000-0002-8271-540X
Towfique RajNash Family Department of Neuroscience & Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-9355-5704
Jack HumphreyNash Family Department of Neuroscience & Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-6274-6620
Matthew KeussUCL Queen Square Motor Neuron Disease Centre, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, UCL, London, UK.ORCID 0000-0002-2628-4115
Michael WardNational Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, USA.ORCID 0000-0002-5296-8051
Maria SecrierUCL Genetics Institute, Department of Genetics, Evolution and Environment, University College London, London, UK.ORCID 0000-0003-2758-1741
Pietro FrattaUCL Queen Square Motor Neuron Disease Centre, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, UCL, London, UK.ORCID 0000-0002-8762-8188
National Hospital for Neurology and Neurosurgery · GBNational Institute of Neurological Disorders and Stroke · USAllen Institute for Brain Science · USThe Francis Crick Institute · GBUniversity College London · GB

Funding

Human Biomarkers CoreU54NS123743 · NINDS · STANFORD UNIVERSITY · PI FRATTA, PIETRO, GITLER, AARON D. · 2021 to 2025
$8.2M
Medical Research Council MC_PC_MR/S022708/1Medical Research Council MR/S006508/1NINDS NIH HHS U54 NS123743Wellcome Trust
6 · The paper itself

Abstract

Nuclear depletion and cytoplasmic aggregation of the RNA-binding protein TDP-43 is the hallmark of ALS, occurring in over 97% of cases. A key consequence of TDP-43 nuclear loss is the de-repression of cryptic exons. Whilst TDP-43 regulated cryptic splicing is increasingly well catalogued, cryptic alternative polyadenylation (APA) events, which define the 3' end of last exons, have been largely overlooked, especially when not associated with novel upstream splice junctions. We developed a novel bioinformatic approach to reliably identify distinct APA event types: alternative last exons (ALE), 3'UTR extensions (3'Ext) and intronic polyadenylation (IPA) events. We identified novel neuronal cryptic APA sites induced by TDP-43 loss of function by systematically applying our pipeline to a compendium of publicly available and in house datasets. We find that TDP-43 binding sites and target motifs are enriched at these cryptic events and that TDP-43 can have both repressive and enhancing action on APA. Importantly, all categories of cryptic APA can also be identified in ALS and FTD post mortem brain regions with TDP-43 proteinopathy underlining their potential disease relevance. RNA-seq and Ribo-seq analyses indicate that distinct cryptic APA categories have different downstream effects on transcript and translation. Intriguingly, cryptic 3'Exts occur in multiple transcription factors, such as

Identifiers

PMID38313254
PMCPMC10836071
OpenAlexW4391130407

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.